Trials / Completed
CompletedNCT01487733
Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301
Analysis of HPV and Other Biomarkers in Specimens From ECOG Studies in Recurrent or Metastatic Head and Neck Cancer (E1395 and E3301)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 155 (actual)
- Sponsor
- Eastern Cooperative Oncology Group · Network
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in tissue samples from patients with recurrent or metastatic head and neck cancer treated on ECOG-E1395 and ECOG-E3301.
Detailed description
OBJECTIVES: * To investigate the association between biomarkers (HPV tumor status and ERCC1 expression) and clinical outcomes in a population of patients with recurrent or metastatic head and neck cancer. * To develop the ability to select patients likely to respond to therapy and to avoid treatment with ineffective therapies, especially since these therapies have substantial toxicity. * To estimate response and survival rates of HPV-negative and -positive patients in each study. (exploratory) OUTLINE: Tumor HPV status is determined by in situ hybridization (ISH) and all samples also undergo immunostaining for p16. ERCC1 expression is evaluated with AQUA, a quantitative IHC analysis. Samples are classified into two categories based on their biomarker status: HPV tumor status (negative versus positive), and ERCC1 expression level (low versus high).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | gene expression analysis | |
| GENETIC | in situ hybridization | |
| OTHER | immunohistochemistry staining method | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2011-12-22
- Primary completion
- 2012-01-22
- Completion
- 2012-01-22
- First posted
- 2011-12-07
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT01487733. Inclusion in this directory is not an endorsement.